Tavneos

Amgen lays out plan to boost sales of newly acquired Tepezza

Amgen has a plan to regain the sales momentum of newly acquired drug Tepezza, which was gained in the company's $27.8B buyout of Horizon Therapeutics.

Kevin Dunleavy Oct 31, 2023 11:29am

Amgen bided its time to snatch up ChemoCentryx

Sep 1, 2022 10:55am

'The Top Line': Biogen's changes, most influential CEOs and more

May 6, 2022 6:15am

Wherefore Tavneos? ChemoCentryx and the Brand Institute explain

Apr 12, 2022 10:39am

#FierceMadness: ChemoCentryx beats BioMarin by major margin

Apr 6, 2022 3:00am

ChemoCentryx scores FDA approval for vasculitis drug Tavneos

Oct 8, 2021 10:08am